Fintel reports that on February 26, 2025, Baird downgraded their outlook for Maravai LifeSciences Holdings (NasdaqGS:MRVI) ...
Maravai LifeSciences (MRVI) stock was downgraded by Baird based on the company's decision to delay its quarterly earnings report and 10-K. Read more here.
Baird downgraded Maravai Lifesciences (MRVI) to Neutral from Outperform with a price target of $3, down from $9, after the company announced ...